About: Effects of Tocilizumab on Mortality in Hospitalized Patients with COVID-19: A Multicenter Cohort Study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effects of Tocilizumab on Mortality in Hospitalized Patients with COVID-19: A Multicenter Cohort Study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Effects of Tocilizumab on Mortality in Hospitalized Patients with COVID-19: A Multicenter Cohort Study
Creator	Moreno, Santiago Herrera, Sabina Martínez-Sanz, Javier Muriel, Alfonso Pérez-Molina, José Ron, Raquel Serrano-Villar, Sergio
Source	MedRxiv
abstract	Background While there are no treatments with proven efficacy for patients with severe coronavirus disease 2019 (COVID 19), tocilizumab has been proposed as a candidate therapy, especially among patients with higher systemic inflammation. Methods We conducted a cohort study of patients hospitalized with COVID 19 in Spain. The primary outcome was time to death and the secondary outcome time to intensive care unit admission (ICU) or death. We used inverse probability weighting to fit marginal structural models adjusted for time varying covariates to determine the causal relationship between tocilizumab use and the outcomes. Results A total of 1,229 and 10,673 person/days were analyzed. In the adjusted marginal structural models, a significant interaction between tocilizumab use and high C reactive protein (CRP) levels was detected. Tocilizumab was associated with decreased risk of death (aHR 0.34, 95% CI 0.16 to 0.72, p=0.005) and ICU admission or death (aHR 0.38, 95% CI 0.19 to 0.81, p=0.011) among patients with baseline CRP >150 mg/L, but not among those with CRP [≤]150 mg/L. Exploratory subgroup analyses yielded point estimates that were consistent with these findings. Conclusions In this large observational study, tocilizumab was associated with a lower risk of death or ICU or death in patients with higher CRP levels. While the results of ongoing clinical trials of tocilizumab in patients with COVID 19 will be important to establish its safety and efficacy, our findings have implications for the design of future clinical trials and support the use of tocilizumab among subjects with higher CRP levels.
has issue date	2020-06-09(xsd:dateTime)
bibo:doi	10.1101/2020.06.08.20125245
has license	medrxiv
sha1sum (hex)	58320d2d67f2b51e2f2296447c85ebdd36936640
schema:url	https://doi.org/10.1101/2020.06.08.20125245
resource representing a document's title	Effects of Tocilizumab on Mortality in Hospitalized Patients with COVID-19: A Multicenter Cohort Study
resource representing a document's body	covid:58320d2d67f2b51e2f2296447c85ebdd36936640#body_text
is schema:about of	named entity 'proven' named entity 'While' named entity 'therapy' named entity 'tocilizumab' named entity 'rate of death' named entity 'urea' named entity 'blood pressure' named entity 'azithromycin' named entity 'emergency department' named entity 'oxygen therapy' named entity 'confounders' named entity 'CRP' named entity 'COVID' named entity 'Spain' named entity 'lymphocyte' named entity 'hypertension' named entity 'observational studies' named entity 'intensive care unit' named entity 'medRxiv' named entity 'preprint' named entity 'preprint' named entity 'preprint' named entity 'tocilizumab' named entity 'interleukin 6' named entity 'confounding' named entity 'risk of death' named entity 'oxygen' named entity 'CRP' named entity 'preprint' named entity 'neutrophil' named entity 'sensitivity analysis' named entity 'COVID' named entity 'confounding' named entity 'lopinavir/ritonavir' named entity 'azithromycin' named entity 'confounding' named entity 'tocilizumab' named entity 'medRxiv' named entity 'CRP' named entity 'missing data' named entity 'control group' named entity 'oxygen' named entity 'ICU' named entity 'ferritin' named entity 'COVID' named entity 'neutrophil' named entity 'tocilizumab' named entity 'biomarker' named entity 'clinical trials' named entity 'tocilizumab' named entity 'clinical trials' named entity 'tocilizumab' named entity 'preprint' named entity 'oxygen' named entity 'preprint' named entity 'confounding' named entity 'tocilizumab' named entity 'inflammatory diseases' named entity 'hypertension' named entity 'Tocilizumab' named entity 'end point' named entity 'Kaplan-Meier' named entity 'vital signs' named entity 'lymphocyte' named entity 'lopinavir/ritonavir' named entity 'Kaplan-Meier' named entity 'discrete time' named entity 'confounders' named entity 'Stata' named entity 'modeling strategy' named entity 'clinical progression' named entity 'D-dimer' named entity 'observational studies' named entity 'randomized trials' named entity 'CRP' named entity 'lymphocyte' named entity 'ICU' named entity 'IL-6 receptor' named entity 'inflammation'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software